Interventions for treating tuberculous pericarditis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 9, 2017, Pages

  Wiysonge, Charles S ^a,b   Ntsekhe, Mpiko ^c   Thabane, Lehana ^d   Volmink, Jimmy ^b   Majombozi, Dumisani ^b   Gumedze, Freedom ^e   Pandie, Shaheen ^e   Mayosi, Bongani M ^e  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; COLCHICINE; CORTISONE; PLACEBO; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE HEXACETONIDE; CORTICOSTEROID; TUBERCULOSTATIC AGENT;

ALL CAUSE MORTALITY; CARDIOVASCULAR MORTALITY; CHEMOTHERAPY; CONSERVATIVE TREATMENT; CONSTRICTIVE PERICARDITIS; FIBRINOLYTIC THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MALIGNANT NEOPLASM; MYCOBACTERIUM INDICUS PRANII; OPPORTUNISTIC INFECTION; PERICARDIAL EFFUSION; PERICARDIECTOMY; PERICARDIOCENTESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL DRAINAGE; SYSTEMATIC REVIEW; TUBERCULOUS PERICARDITIS; CAUSE OF DEATH; COMPLICATION; META ANALYSIS; MORTALITY; PERICARDIUM; SERODIAGNOSIS;

ADRENAL CORTEX HORMONES; ANTITUBERCULAR AGENTS; CAUSE OF DEATH; COLCHICINE; DRAINAGE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; IMMUNOTHERAPY; PERICARDIECTOMY; PERICARDITIS, TUBERCULOUS; PERICARDIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85029357349     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000526.pub2     Document Type: Review

References (69)

1. Hakim J, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjuvant prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000;84(2):183-8. 3382849
2. Hakim JG, Ternouth I, Mushangi E. Mortality in patients with HIV-related tuberculous pericarditis (TBP) treated with adjunctive prednisolone [abstract]. International Clinical Epidemiology Network. Abstracts of the INCLEN XV Global Meeting, 1998, Queretaro, Mexico. Journal of Clinical Epidemiology 1998;51(Suppl 1):5S. 3382850
3. Liebenberg JJ, Dold CJ, Olivier LR. A prospective investigation into the effect of colchicine on tuberculous pericarditis. Cardiovascular Journal of Africa 2016;27(6):350-5. 6678223
4. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. New England Journal of Medicine 2014;371(12):1121-30. 3382852
5. Mayosi BM, Ntsekhe M, Bosch J, Pogue J, Gumedze F, Badri M, et al. Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. American Heart Journal 2013;165(2):109-15.e3. 3382853
6. Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovascular Journal of South Africa 2006;17(5):233-8. 3382855
7. Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases over a six-year period. South African Medical Journal 1959;33:810-7. 3382857
8. Strang JI, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM 2004;97(8):525-35. 3382859
9. Strang JIG, Kakaza HHS, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis. Lancet 1987;2(8573):1418-22. 3382860
10. Strang JI, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM 2004;97(8):525-35. 3382862
11. Strang JIG, Kakaza HHS, Gibson DG, Allen BW, Mitchison DA, Evans DJ, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988;2(8614):759-64. 3382863
12. Wiysonge CS, Ntsekhe M, Gumedze F, Sliwa K, Blackett KN, Commerford PJ, et al. Contemporary use of adjunctive corticosteroids in tuberculous pericarditis. International Journal of Cardiology 2008;124(3):388-90. 3382865
13. Cui HB, Chen XY, Cui CC, Shou XL, Liu XH, Yao XW, et al. Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase. Chinese Medical Sciences Journal 2005;20(1):5-10. 3382867
14. NCT02673879. IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion (IMPI-2). https://clinicaltrials.gov/ct2/show/NCT02673879 (first received 1 February 2016). 6678225
15. Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tubercle and Lung Disease 1993;74(1):6-11.
16. Augustin P, Desmard M, Mordant P, Lasocki S, Maury JM, Heming N, et al. Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis. Critical Care 2011;15(2):220. [DOI: 10.1186/cc10022]
17. Balshem B, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
18. Bhan GL. Tuberculous pericarditis. Journal of Infection 1980;2(4):360-4.
19. Cegielski JP, Ramaiya K, Lallinger GJ, Mtulia IA, Mbaga IM. Pericardial disease and human immunodeficiency virus in Dar es Salaam, Tanzania. Lancet 1990;335(8683):209-12.
20. Cisneros JR, Murray KM. Corticosteroids in tuberculosis. Annals of Pharmacotherapy 1996;30(11):1298-303.
21. Commerford PJ, Strang JIG. Tuberculous pericarditis. In: Coovadia HM, Benatar SR editor(s). A Century of Tuberculosis: South African Perspectives. Cape Town: Oxford University Press, 1991.
22. Desai HN. Tuberculous pericarditis: a review of 100 cases. South African Medical Journal 1979;55(22):877-80.
23. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clinical Infectious Diseases 1997;25(4):872-87.
24. Fowler NO. Tuberculous pericarditis. JAMA 1991;266(1):99-103.
25. Fowler NO. Pericardial disease. Heart Disease & Stroke 1992;1(2):85-94.
26. Fowler NO. Constrictive pericarditis: its history and current status. Clinical Cardiology 1995;18(6):341-50.
27. Ganju L, Mukherjee R, Batra HV, Talwar GP. Immuno-blot analysis of antigens of Mycobacterium w: a candidate anti-leprosy vaccine using monoclonal antibodies and patient sera. Zentralblatt für Bakteriologie 1990;273(3):378-85.
28. Gelfand M. The Sick African. The Sick African. 3rd Edition. Cape Town: Juta, 1957:447.
29. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 15 September 2014. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
31. Harvey AM, Whitehill MR. Tuberculous pericarditis. Medicine 1937;16:45-94.
32. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
33. Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA 2015;314(14):1498-506.
34. Kliner M, Garner P. When trial authors write Cochrane Reviews: competing interests need to be better managed [editorial]. Cochrane Database of Systematic Reviews 2014; Vol. 9:10.1002/14651858.ED000089.
35. Koh KK, Kim EJ, Cho CH, Choi MJ, Cho SK, Kim SS, et al. Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis. Circulation 1994;89(6):2728-35.
36. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011;378(9785):57-72.
37. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
38. Lorell BH. Pericardial diseases. In: Braunwald E editor(s). Heart disease: a Textbook of Cardiovascular Medicine. Philadelphia: W.B. Saunders, 1997.
39. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993;7(12):1569-79.
40. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007;370(9604):2030-43.
41. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005;112(23):3608-16.
42. Mayosi BM, Wiysonge CS, Ntsekhe M, Volmink JA, Gumedze F, Maartens G, et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infectious Diseases 2006;6:2.
43. Mayosi BM, Wiysonge CS, Ntsekhe M, Gumedze F, Volmink JA, Maartens G, et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. South African Medical Journal 2008;98(1):36-40.
44. Mutyaba AK, Balkaran S, Cloete R, du Plessis N, Badri M, Brink J, et al. Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa: causes and perioperative outcomes in the HIV era (1990-2012). Journal of Thoracic and Cardiovascular Surgery 2014;148(6):3058-65.e1.
45. Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM 2003;96(8):593-9.
46. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005;112(23):3602-7.
47. Ntsekhe M, Wiysonge CS, Gumedze F, Maartens G, Commerford PJ, Volmink JA, et al. HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study. PLoS ONE 2008;3(6):e2253.
48. Ntsekhe M, Shey Wiysonge C, Commerford PJ, Mayosi BM. The prevalence and outcome of effusive constrictive pericarditis: a systematic review of the literature. Cardiovascular Journal of Africa 2012;23(5):281-5.
49. Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Failure Reviews 2013;18(3):367-73.
50. Pandie S, Engel ME, Kerbelker ZS, Mayosi BM. Mycobacterium w immunotherapy for treating pulmonary tuberculosis - a systematic review. Current Pharmaceutical Design 2014;20(39):6207-14.
51. Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, et al. Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. EBioMedicine 2015;2(11):1634-9.
52. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA 2012;308(16):1676-84.
53. Quayle JM, Lipschik GY, Heurich AE. Management of tuberculous pericarditis. Annals of Thoracic Surgery 1987;43(6):653-5.
54. Rana F, Hawken MP, Meme HK, Chakaya JM, Githui WA, Odhiambo JA, et al. Autopsy findings in HIV-1-infected adults in Kenya. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997;14(1):83-5.
55. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
56. Rooney JJ, Crocco JA, Lyons HA. Tuberculous pericarditis. Annals of Internal Medicine 1970;72(1):73-8.
57. Sagristà-Sauleda J, Permanya-Miralda G, Soler-Soler J. Tuberculous pericarditis: ten year experience with a prospective protocol for diagnosis and treatment. Journal of the American College of Cardiology 1988;11(4):724-8.
58. Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, Hasnain SE, et al. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS ONE 2009;4(7):e6263.
59. Schrire V. Pericarditis (with particular reference to tuberculous pericarditis). Australian Annals of Medicine 1967;16(1):41-51.
60. Senderovitz T, Viskum K. Corticosteroids and tuberculosis. Respiratory Medicine 1994;88(8):561-5.
61. Shenje J, Ifeoma Adimora-Nweke F, Ross IL, Ntsekhe M, Wiesner L, Deffur A, et al. Poor penetration of antibiotics into pericardium in pericardial tuberculosis. EBioMedicine 2015;2(11):1640-9.
62. Singh IG, Mukherjee R, Talwar GP, Kaufmann SH. In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infection and Immunity 1992;60(1):257-63.
63. Strang JIG. Tuberculous pericarditis in Transkei. Clinical Cardiology 1984;7(12):667-70.
64. Strang JIG. Tuberculous pericarditis. Journal of Infection 1997;35(3):215-9.
65. Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Progress in Cardiovascular Diseases 2007;50(3):218-36.
66. Wiysonge CS. Immunotherapy for tuberculous pericarditis. New England Journal of Medicine 2014;371(26):2533. [DOI: 10.1056/NEJMc1413185#SA4]
67. Zumla A, Maeurer M, Moll G, Mayosi BM. Host-directed therapies for tuberculous pericarditis. International Journal of Infectious Diseases 2015;32:30-1.
68. Mayosi BM, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000526]
69. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD000526]